15-PGDH Inhibitor

SW033291 is a potent and high-affinity inhibitor of 15-PGDH with a K_i of 0.1 nM. SW033291 increases prostaglandin PGE2 levels in bone marrow and other tissues. SW033291 also promotes tissue regeneration.

MF-DH-300 is a 15-PGDH inhibitor that can be applicable to the research of muscle disorders such as spinal muscular atrophy (SMA).

ML148 is a potent and selective 15-PGDH inhibitor with an IC₅₀ of 56 nM. ML148 has the potential for the research of prostaglandin-signaling pathways.

15-PGDH-IN-1 is a potent and orally active 15-PGDH inhibitior. 15-PGDH-IN-1 has inhibition activity against recombinant human 15-PGDH with an IC₅₀ value of 3 nM. 15-PGDH-IN-1 can be used for the research of tissue repair and regeneration.

HW201877 is a potent and orally active 15-prostaglandin dehydrogenase (15-PGDH) inhibitor with an IC₅₀ of 3.6 nM. HW201877 demonstrates robust cellular efficacy in elevating PGE2 levels in A549 cells and exhibits remarkable efficacy in animal models of tissue injury and fibrosis. HW201877 can be used for the study of inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and Crohn’s disease (CD).

HW201877 enantiomer is the enantiomer of HW201877 (HY-174990) and is 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitor with an IC₅₀ of 12.2 nM. HW201877 enantiomer can be used for the research of inflammatory bowel disease, idiopathic pulmonary fibrosis, ulcerative colitis, and Crohn's disease.

15-PGDH-IN-5 (compound 5) is a sulfoxide-derived 15-PGDH inhibitor. 15-PGDH-IN-5 exhibits higher metabolic stability and superior in vivo exposure compared with the lead compound SW033291 (HY-16968). 15-PGDH-IN-5 inhibits the irreversible oxidative catabolism of PGE2 by 15-PGDH, thereby enhancing the tissue-specific bioavailability of endogenous PGE2. 15-PGDH-IN-5 exerts anti-inflammatory effects and accelerates tissue repair and regeneration, and it is used in studies on tissue injury and fibrosis-related diseases such as inflammatory bowel disease and idiopathic pulmonary fibrosis.

MF-PGDH-008 serves as an inhibitor of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH).

15-PGDH-IN-3 (Compound 61) is a selective competitive inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-PGDH).

15-PGDH-IN-4 (Compound 40) is a 15-PGDH inhibitor with an IC₅₀ of 1.2 nM against h15-PGDH. 15-PGDH-IN-4 functionally inhibits the activity of 15-PGDH. 15-PGDH-IN-4 can be used in the research of colitis.

CAY10397 is a selective and orally active 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitor. CAY10397 can inhibit 15-PGDH-dependent endogenous metabolite production. CAY10397 blocks the selenium-dependent protective in inflammation. CAY10397 can be used for the research of colitis.

15-epi-PGE1 (15R-Prostaglandin E1; 15-Epiprostaglandin E1) is a stereoisomer of PGE1 (HY-B0131) but with less biological activity. 15-epi-PGE1 is a non-competitive inhibitor for human placental 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) with an IC₅₀ of 170 μM.

(R)-SW033291 is the R-type enantiomer of SW033291 (HY-16968). (R)-SW033291 is a potent and high-affinity inhibitor of 15-PGDH. (R)-SW033291 increases prostaglandin PGE2 levels in bone marrow and other tissues. (R)-SW033291 also promotes tissue regeneration.

15-PGDH-IN-2 (Compound 2) is a 15-PGDH inhibitor with an IC₅₀ value of 0.274 nM. 15-PGDH-IN-2 can be used in research on hair loss, bone formation, gastric ulcer healing, and dermal wound healing.

5-Hydroxy prostaglandin dehydrogenase blocking peptide (15-PGDH (92-105)) is a blocking peptide that corresponds to the amino acids (AGVNNEKNWEKTLQ) located at positions 92-105 of the 15-hydroxy prostaglandin dehydrogenase (15-PGDH) sequence. 5-Hydroxy prostaglandin dehydrogenase blocking peptide can block the formation of protein-antibody complexes during immunohistochemical analysis of 15-PGDH.

Ph CL 28A is a prostaglandin dehydrogenase (PGDH) inhibitor. Ph CL 28A increases the output of PGE2, PGF2α and endogenous arachidonic acid-derived PGI2 in isolated rat lungs, reduces the output of TxB2 and LTC4 in isolated rat hearts, and exhibits protective effects in rat models of inflammation and gastric mucosal injury. Ph CL 28A can be used in research related to acute inflammation and gastric ulcers.